Perivascular macrophages and lung blood vessel repair after severe lung injury
Perivascular macrophages - a new player in regulating endothelial repair following lung vascular injury
Looks at whether immune cells called perivascular macrophages and tiny particles they release can help repair damaged lung blood vessels in adults with ARDS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11303456 on NIH RePORTER |
What this research studies
The team will use advanced live imaging in mouse lungs to watch how perivascular macrophages and blood vessel cells interact after lung injury. They will remove these macrophages genetically to see if loss of the cells slows repair, and they will transfer extra macrophages into injured lungs to see if adding them speeds healing. Researchers will analyze tiny vesicles called exosomes and a molecule called glutaminase that these macrophages may use to communicate with endothelial cells. The findings are intended to point toward new ways to boost blood-vessel healing in ARDS.
Who could benefit from this research
Good fit: Adults with ARDS or severe acute lung injury treated in hospitals would be the likely candidates for any future therapies developed from this research.
Not a fit: Patients with chronic non-vascular lung diseases, stable chronic respiratory conditions, or those needing immediate bedside treatments may not benefit directly from this early-stage laboratory research.
Why it matters
Potential benefit: If successful, this work could lead to treatments that speed repair of lung blood vessels, reduce fluid leakage into the lungs, and improve recovery from ARDS.
How similar studies have performed: Previous studies show some macrophage types can support tissue repair, but focusing on perivascular macrophages, their exosomes, and glutaminase for lung endothelial repair is a novel approach.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Zhou, Bisheng — University of Illinois at Chicago
- Study coordinator: Zhou, Bisheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.